BizJournals |
August 11th, 2008 |
Email this
EXTON — More than 500 hospitals have enrolled in Adolor Corp.’s Entereg access support and education program since the product was launched in June.[...]
The Food and Drug Administration said Adolor Corp. could resume clinical testing of its drug Entereg to treat bowel discomfort commonly associated with use of opioid painkillers, the Exton company said today.[...]
Denmark's Santaris Pharma announced that Soren Tulstrup, previously vice president, global human health at Merck, has been appointed president and chief executive officer. Danube Pharmaceuticals has named Dr. Barrett Katz, MD, MBA as its chief executive officer. Creabilis Therapeutics has named Tony Wilson chief executive officer. Opexa Therapeutics has appointed [...]
CNBC |
June 13th, 2008 |
Email this
Biopharmaceutical company Adolor Corp. said Friday it appointed Stephen W. Webster as chief financial officer, effective on or about June 30. Read More Permalink[...]
Restructuring charges bit into Talbots Inc.'s bottom line, and the stock is reeling in premarket action, losing 15%, according to Archipelago. The women's retailer said net income fell to $1.6 million, or three cents a share. The company reaffirmed its guidance for fiscal-year earnings excluding items of 47 cents to [...]
Adolor Corp. and GlaxoSmithKline P.L.C. won a four-year struggle yesterday to sell the first U.S. treatment for constipation after intestinal surgery.[...]
CNBC |
May 20th, 2008 |
Email this
Drug developers GlaxoSmithKline and Adolor Corp. said Tuesday the Food and Drug Administration approved their anti-constipation drug Entereg. Read More Permalink[...]
CNBC |
May 9th, 2008 |
Email this
Adolor Corp. said Friday that the Food and Drug Administration won't be making a decision on approval of the company's Entereg drug for post-surgery bowel blockage by Saturday, the scheduled action date. Read More Permalink[...]
Drug company Adolor Corp. today said it narrowed its fourth-quarter and annual losses even though revenue dropped at the Exton firm as it awaited the outcome of a federal review of a key new medication.[...]
Why pay so much attention to small drug companies that never seem to get a drug approved? The question came up last week as Adolor Corp. went before an advisory panel of the Food and Drug Administration seeking approval of its first drug. Implicit in the question is that small [...]
The benefits of Adolor Corp.'s only product, the specialized bowel medicine Entereg, outweighed potential risks, including heart attacks, medical experts said yesterday.[...]
Adolor Corp. of Exton faces a crucial hurdle today in its effort to get its first product, the bowel drug Entereg, approved by U.S. regulators to sell.[...]
There are a number of times in a small drug company's development when it faces crucial tests. Exton-based Adolor Corp. confronts one this week when it goes before a panel of advisers to the Food and Drug Administration over its compound to treat consti-[...]
WASHINGTON - Shares of Adolor Corp. soared yesterday after government reviewers said the Exton company's drug appears effective at treating severe constipation that follows surgery.[...]
Shares of Adolor Corp. shot up 21 percent today after the tiny Exton company said Pfizer Inc. will pay much of the development and commercialization expenses for two new pain drugs.[...]
CNBC |
December 5th, 2007 |
Email this
Shares of biotechnology company Adolor Corp. jumped Wednesday after the company said Pfizer Inc. will cover most of the expenses for developing two of Adolor's pain drug candidates and will market the drugs if they are approved. Read More Permalink[...]
